Marinus Pharmaceuticals, Inc.
MRNS · NASDAQ
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $42 | $65 | $104 | $121 |
| Short-Term Investments | $0 | $0 | $9 | $30 |
| Receivables | $4 | $3 | $4 | $4 |
| Inventory | $7 | $5 | $6 | $2 |
| Other Curr. Assets | $5 | $9 | $9 | $9 |
| Total Curr. Assets | $57 | $82 | $131 | $165 |
| Property Plant & Equip (Net) | $5 | $4 | $5 | $5 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $1 | $1 | $1 | $1 |
| Total NC Assets | $6 | $5 | $6 | $6 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $64 | $87 | $137 | $171 |
| Liabilities | – | – | – | – |
| Payables | $4 | $6 | $6 | $4 |
| Short-Term Debt | $14 | $12 | $17 | $15 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $0 | $0 | $0 | $0 |
| Other Curr. Liab. | $17 | $17 | $20 | $22 |
| Total Curr. Liab. | $35 | $36 | $43 | $41 |
| LT Debt | $42 | $81 | $93 | $96 |
| Deferred Rev, NC | $36 | $18 | $18 | $18 |
| Deferred Tax Liab, NC | $0 | $0 | -$18 | $0 |
| Other NC Liab. | $18 | $0 | $0 | $0 |
| Total NC Liab. | $96 | $99 | $111 | $114 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $1 | $1 | $2 | $1 |
| Total Liabilities | $130 | $134 | $154 | $154 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Retained Earnings | -$671 | -$646 | -$611 | -$572 |
| AOCI | $0 | $0 | $0 | -$0 |
| Other Equity | $604 | $599 | $594 | $589 |
| Total Equity | -$67 | -$47 | -$16 | $17 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $64 | $87 | $137 | $171 |
| Net Debt | $14 | $28 | $6 | -$10 |